2021
Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection
Nagai M, Moriyama M, Ichinohe T. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. MBio 2021, 12: 10.1128/mbio.01598-21. PMID: 34399617, PMCID: PMC8406166, DOI: 10.1128/mbio.01598-21.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralBacteriaCell LineChlorocebus aethiopsCOVID-19COVID-19 VaccinesDogsHemagglutinin Glycoproteins, Influenza VirusImmunity, MucosalInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesMadin Darby Canine Kidney CellsMiceMice, Inbred BALB CMyeloid Differentiation Factor 88Nasal MucosaOrthomyxoviridae InfectionsPathogen-Associated Molecular Pattern MoleculesSARS-CoV-2VaccinationVero CellsConceptsInfluenza virus infectionVirus-specific adaptive immunityVaccine-specific antibody responseVirus-specific antibody responsesAntibody responseMyD88-dependent mannerVirus infectionHealthy human volunteersPathogen-associated molecular patternsImmune responseNasal bacteriaOral bacteriaCommensal bacteriaIntranasal supplementationHA vaccineVaccine protectsIntranasal vaccineIntranasal administrationIntranasal applicationAdaptive immunityOral cavityAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere acute respiratory syndrome coronavirus 2Influenza virus hemagglutinin vaccine
2017
Induction of lung CD8+ T cell responses by consecutive inoculations of a poly(I:C) influenza vaccine
Moriyama M, Takeyama H, Hasegawa H, Ichinohe T. Induction of lung CD8+ T cell responses by consecutive inoculations of a poly(I:C) influenza vaccine. Vaccine 2017, 35: 6620-6626. PMID: 29079103, DOI: 10.1016/j.vaccine.2017.10.038.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralCD8-Positive T-LymphocytesCross ProtectionImmunoglobulin AInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesLungMiceMice, Inbred BALB COrthomyxoviridae InfectionsPoly I-CT-Lymphocytes, CytotoxicVaccinationVaccines, InactivatedConceptsMediastinal lymph nodesStrong CTL responsesCTL responsesIntranasal vaccinationInfluenza vaccineVirus vaccineInfluenza virus-specific CD8Cytotoxic T lymphocyte responsesInfluenza virusHeterologous influenza virusesVirus-specific CD8T lymphocyte responsesT cell responsesInfluenza virus infectionInfluenza virus vaccineWhole virus vaccineLung CD8Respiratory DCsVaccine elicitsLymph nodesLymphocyte responsesIntranasal administrationConsecutive vaccinationsT cellsVirus infectionConsecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge
Moriyama M, Chino S, Ichinohe T. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge. Vaccine 2017, 35: 1001-1007. PMID: 28111142, DOI: 10.1016/j.vaccine.2017.01.025.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralCross ProtectionFemaleFormaldehydeImmunity, MucosalImmunization ScheduleImmunoglobulin AImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesMiceMice, Inbred BALB COrthomyxoviridae InfectionsPoly I-CSurvival AnalysisVaccines, InactivatedConceptsInfluenza virus vaccinePrimary immune responseVirus vaccineIntranasal vaccinationVirus challengeImmune responseInactivated influenza virus vaccineInfluenza virusHeterologous influenza virus challengeVirus-specific IgAInfluenza virus challengeHeterologous virus challengeNatural infectionSerum IgG responsesConsecutive inoculationsSingle intranasal vaccinationCross-protective activityNasal IgANasal washesIgG responsesMucosal immunitySystemic immunityVaccinationNaïve animalsVaccine